Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The collaboration between CORONA and Ferring will cater to patients across India
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Specialty Chemicals grew 38% YoY for FY23
Subscribe To Our Newsletter & Stay Updated
